Study identifier:RO-2455-401-BE
ClinicalTrials.gov identifier:NCT02128529
EudraCT identifier:N/A
CTIS identifier:N/A
A cross-sectional observational study in pulmonology departments in Belgium and Luxembourg to investigate the epidemiology of chronic bronchitis in patients suffering from moderate to very severe COPD
Chronic Obstructive Pulmonary Disease
-
No
-
All
976
Observational
40 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
The purpose of this study was to investigate the prevalence of chronic bronchitis in patients suffering from moderate to very severe chronic obstructive pulmonary disease (COPD), and to assess the difference in exacerbation rates in patients suffering from moderate to very severe COPD with chronic bronchitis vs. a population of patients without chronic bronchitis.
This was an observational study so participants only took medication that was prescribed by their regular healthcare provider. No additional study medication was administered. This study enrolled patients who were previously diagnosed with moderate to very severe chronic obstructive pulmonary disease (COPD). This study looked at the prevalence of chronic bronchitis in patients suffering from moderate, severe or very severe COPD, and it also compared worsening of COPD in patients with or without chronic bronchitis. This study enrolled 976 patients. This multi-centre trial was conducted in Belgium and Luxembourg. The overall time to participate in this study was at a single, regularly scheduled visit at the pulmonologists office. There were no follow-up assessments for this study.
No locations available
Arms | Assigned Interventions |
---|---|
Chronic obstructive pulmonary disease Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records. | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.